PMID- 33110100
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210803
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Oct 27
TI  - A role for the immune system in advanced laryngeal cancer.
PG  - 18327
LID - 10.1038/s41598-020-73747-0 [doi]
LID - 18327
AB  - To investigate the role of the altered activation of the immune system in the 
      prognosis of patients affected by laryngeal squamous cell carcinoma (LSCC). We 
      analyzed 56 patients with advanced LSCC divided into two groups according to 
      their prognosis: the first group relapsed within 24 months after treatment, the 
      second group had no evidence of disease at 2 years. The presence of stromal tumor 
      infiltrating lymphocytes (TILs) at the tumor-host border was investigated. In 43 
      patients we evaluated the expression of 395 genes related to immune system 
      activation through a next generation sequencing panel. Priority-LASSO models and 
      clustering analyses were integrated with multivariate Cox proportional hazard 
      modeling to identify independent genes associated with relapse and estimate 
      hazard ratios in relation to gene expression and TILs. TILs and the expression of 
      genes related with immune system activation (FCGR1A, IFNA17, FCRLA, NCR3, 
      KREMEN1, CD14, CD3G, CD19, CD20 and CD79A) were significantly associated with 
      prognostic factors or disease specific survival. In patients with lymph node 
      metastases and advanced T stage (pT4), the expression of other genes was altered. 
      Low TILs count was highly associated with relapse within 2 years (p < 0.001). Low 
      TILs and altered expression of specific genes associated with tumor-immune 
      systems interactions emerged as independent risk factors, associated to poor 
      prognosis and relapse within 2 years in advanced LSCC. Evaluation of patients' 
      immune profile could be useful for prognosis and future therapeutic approaches 
      towards personalized therapy.
FAU - Tagliabue, Marta
AU  - Tagliabue M
AD  - Division of Otolaryngology and Head and Neck Surgery, IEO, European Institute of 
      Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy. marta.tagliabue@ieo.it.
FAU - Maffini, Fausto
AU  - Maffini F
AD  - Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 
      435, 20141, Milan, Italy.
FAU - Fumagalli, Caterina
AU  - Fumagalli C
AD  - Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 
      435, 20141, Milan, Italy.
FAU - Gandini, Sara
AU  - Gandini S
AD  - Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 
      Via Adamello 16, 20139, Milan, Italy.
FAU - Lepanto, Daniela
AU  - Lepanto D
AD  - Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 
      435, 20141, Milan, Italy.
FAU - Corso, Federica
AU  - Corso F
AD  - Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 
      Via Adamello 16, 20139, Milan, Italy.
FAU - Cacciola, Salvatore
AU  - Cacciola S
AD  - Division of Otolaryngology and Head and Neck Surgery, IEO, European Institute of 
      Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
FAU - Ranghiero, Alberto
AU  - Ranghiero A
AD  - Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 
      435, 20141, Milan, Italy.
FAU - Rappa, Alessandra
AU  - Rappa A
AD  - Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 
      435, 20141, Milan, Italy.
FAU - Vacirca, Davide
AU  - Vacirca D
AD  - Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 
      435, 20141, Milan, Italy.
FAU - Cossu Rocca, Maria
AU  - Cossu Rocca M
AD  - Department of Medical Oncology, Urogenital and Head and Neck Tumors Medical 
      Treatment, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, 
      Milan, Italy.
FAU - Alterio, Daniela
AU  - Alterio D
AD  - Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via 
      Ripamonti 435, 20141, Milan, Italy.
FAU - Guerini Rocco, Elena
AU  - Guerini Rocco E
AD  - Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 
      435, 20141, Milan, Italy.
AD  - Department of Oncology and Hemato-Oncology, School of Medicine, State University 
      of Milan, Milan, Italy.
FAU - Cattaneo, Augusto
AU  - Cattaneo A
AD  - Division of Otolaryngology and Head and Neck Surgery, IEO, European Institute of 
      Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
FAU - Chu, Francesco
AU  - Chu F
AD  - Division of Otolaryngology and Head and Neck Surgery, IEO, European Institute of 
      Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
FAU - Zorzi, Stefano
AU  - Zorzi S
AD  - Division of Otolaryngology and Head and Neck Surgery, IEO, European Institute of 
      Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
FAU - Curigliano, Giuseppe
AU  - Curigliano G
AD  - Department of Oncology and Hemato-Oncology, School of Medicine, State University 
      of Milan, Milan, Italy.
AD  - Division of Early Drug Development for Innovative Therapies, IEO, European 
      Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
FAU - Chiocca, Susanna
AU  - Chiocca S
AD  - Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 
      Via Adamello 16, 20139, Milan, Italy.
FAU - Barberis, Massimo
AU  - Barberis M
AD  - Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 
      435, 20141, Milan, Italy.
FAU - Viale, Giuseppe
AU  - Viale G
AD  - Division of Pathology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 
      435, 20141, Milan, Italy.
AD  - Department of Oncology and Hemato-Oncology, School of Medicine, State University 
      of Milan, Milan, Italy.
FAU - Ansarin, Mohssen
AU  - Ansarin M
AD  - Division of Otolaryngology and Head and Neck Surgery, IEO, European Institute of 
      Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
EIN - Sci Rep. 2021 May 3;11(1):9760. PMID: 33941821
MH  - Aged
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Humans
MH  - Immunity/genetics/immunology
MH  - Laryngeal Neoplasms/diagnosis/*immunology/pathology
MH  - Lymphocytes, Tumor-Infiltrating/immunology/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/immunology/metabolism
MH  - Prognosis
MH  - Retrospective Studies
MH  - Sequence Analysis, RNA
PMC - PMC7591515
COIS- The authors declare no competing interests.
EDAT- 2020/10/29 06:00
MHDA- 2021/02/27 06:00
PMCR- 2020/10/27
CRDT- 2020/10/28 05:35
PHST- 2020/04/26 00:00 [received]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/10/28 05:35 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2020/10/27 00:00 [pmc-release]
AID - 10.1038/s41598-020-73747-0 [pii]
AID - 73747 [pii]
AID - 10.1038/s41598-020-73747-0 [doi]
PST - epublish
SO  - Sci Rep. 2020 Oct 27;10(1):18327. doi: 10.1038/s41598-020-73747-0.